| 1 |
NCT02596828 |
Recruiting |
Prospective Pilot Trial to Assess a Multimodal Molecular Targeted Therapy in Children, Adolescent and Young Adults With Relapsed or Refractory High-grade Pineoblastoma |
|
- Drug: Temozolomide
- Drug: Irinotecan
- Drug: Dasatinib
- Drug: Rapamycin
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- The primary endpoint is progression-free survival (PFS)
- Overall survival (OS)
- Response to the investigational treatment after 4 and 8 courses of I/T and 1-year-follow-up in the RIST treatment arm
- (and 4 more...)
|
4 |
All |
up to 25 Years (Child, Adult) |
NCT02596828 |
RIST-rPB-2015-P |
|
April 2016 |
April 2019 |
April 2020 |
November 4, 2015 |
December 30, 2016 |
|
- University Hospital of Regensburg
Regensburg, Germany
|
| 2 |
NCT01063114 |
Active, not recruiting |
Proton Beam Radiotherapy for Medulloblastoma and Pineoblastoma |
- Brain Tumor
- Medulloblastoma
- Pineoblastoma
|
- Radiation: proton beam radiation
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- M.D. Anderson Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Ototoxicity
- Endocrine dysfunction
- Neurocognitive Effects
- (and 3 more...)
|
90 |
All |
3 Years to 25 Years (Child, Adult) |
NCT01063114 |
09-361
P01CA021239 |
|
April 2010 |
April 2018 |
April 2024 |
February 5, 2010 |
October 17, 2017 |
|
- Massachusetts General Hospital
Boston, Massachusetts, United States - MD Anderson Cancer Center
Houston, Texas, United States
|
| 3 |
NCT01884194 |
Completed |
Morphological Analysis of the Pineal Gland in Pediatric Retinoblastoma Patients Using Magnetic Resonance Imaging |
- Retinoblastoma
- Pineoblastoma
|
|
Observational |
|
- Charite University, Berlin, Germany
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Malignancy criteria of pineal gland
|
80 |
All |
up to 50 Years (Child, Adult) |
NCT01884194 |
RTB_0305_outcome |
|
November 2013 |
December 2014 |
February 2015 |
June 21, 2013 |
December 29, 2015 |
|
- Charite Hospital Berlin
Berlin, Germany
|
| 4 |
NCT00105560 |
Active, not recruiting
Has Results |
Proton Beam Radiation Therapy in Treating Young Patients Who Have Undergone Biopsy or Surgery for Medulloblastoma or Pineoblastoma |
- Brain and Central Nervous System Tumors
- Long-term Effects Secondary to Cancer Therapy in Children
|
- Radiation: radiation therapy
|
Interventional |
Not Applicable |
- Massachusetts General Hospital
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Cumulative Incidence of Ototoxicity
- Cumulative Incidence of Endocrine Dysfunction (Neuroendocrine and End Organ Defects) at 3 Years
- Cumulative Incidence of Endocrine Dysfunction (Neuroendocrine and End Organ Defects) at 5 Years
- (and 5 more...)
|
59 |
All |
3 Years to 21 Years (Child, Adult) |
NCT00105560 |
CDR0000415841
P01CA021239
MGH-99-271 |
|
May 2002 |
December 2012 |
December 2021 |
March 16, 2005 |
October 16, 2017 |
August 21, 2017 |
- Massachusetts General Hospital
Boston, Massachusetts, United States
|
| 5 |
NCT02417324 |
Recruiting |
International HIT-MED Registry (I-HIT-MED) |
|
|
Observational |
|
- Universitätsklinikum Hamburg-Eppendorf
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Event free survival
- Pattern of relapse
- Overall survival
|
500 |
All |
Child, Adult, Senior |
NCT02417324 |
I-HIT-MED Registry |
|
January 2015 |
December 2019 |
December 2024 |
April 15, 2015 |
October 18, 2017 |
|
- University Hospital Aachen
Aachen, Germany - Klinikum Augsburg
Augsburg, Germany - Helios Klinikum Berlin-Buch
Berlin, Germany - (and 54 more...)
|
| 6 |
NCT01217437 |
Active, not recruiting |
Temozolomide and Irinotecan Hydrochloride With or Without Bevacizumab in Treating Young Patients With Recurrent or Refractory Medulloblastoma or CNS Primitive Neuroectodermal Tumors |
- Recurrent Childhood Medulloblastoma
- Recurrent Childhood Pineoblastoma
- Recurrent Childhood Supratentorial Embryonal Tumor, Not Otherwise Specified
|
- Biological: Bevacizumab
- Drug: Irinotecan Hydrochloride
- Drug: Temozolomide
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall survival for each treatment arm
- Response rate for each treatment arm
- Event-free survival
|
120 |
All |
up to 21 Years (Child, Adult) |
NCT01217437 |
NCI-2011-02605
11-00909
CDR0000686608
ACNS0821
COG-ACNS0821
U10CA180886
U10CA098543 |
|
November 22, 2010 |
March 1, 2018 |
|
October 8, 2010 |
March 5, 2018 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham Cancer Center
Birmingham, Alabama, United States - Phoenix Childrens Hospital
Phoenix, Arizona, United States - (and 155 more...)
|
| 7 |
NCT00392327 |
Recruiting |
Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma |
- Untreated Childhood Medulloblastoma
- Untreated Childhood Pineoblastoma
- Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
|
- Radiation: Radiation Therapy
- Drug: Vincristine Sulfate
- Drug: Carboplatin
- (and 6 more...)
|
Interventional |
Phase 3 |
- Children's Oncology Group
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Event-free survival (EFS) percentage
- Tumor response to radiation therapy with or without carboplatin
- Time to death
|
400 |
All |
3 Years to 21 Years (Child, Adult) |
NCT00392327 |
ACNS0332
NCI-2009-00336
COG-ACNS0332
CDR0000511991
R01CA114567
U10CA180886
U10CA098543 |
|
March 2007 |
June 2018 |
|
October 26, 2006 |
August 31, 2017 |
|
- Children's Hospital of Alabama
Birmingham, Alabama, United States - University of Alabama at Birmingham
Birmingham, Alabama, United States - Arkansas Children's Hospital
Little Rock, Arkansas, United States - (and 183 more...)
|
| 8 |
NCT00179803 |
Unknown † |
Stem Cell Transplant for High Risk Central Nervous System (CNS) Tumors |
- Glioblastoma
- Astrocytoma
- Pineoblastoma
- (and 2 more...)
|
- Procedure: Stem Cell Transplant
|
Interventional |
Phase 2
Phase 3 |
- Ann & Robert H Lurie Children's Hospital of Chicago
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- To determine if the use of sequential myeloablative chemotherapy with peripheral blood stem cell rescue will increase the overall survival rate in patients with newly diagnosed high risk CNS tumors
- The overall survival and progression free survival in children with recurrent CNS malignancies after obtaining a state of minimum residual disease with submyeloablative chemotherapy, surgery, and/or radiation.
- To determine the progression free survival and overall survival using sequential myeloablative chemotherapy as compared to historical controls with single autologous stem cell rescue following myeloablative chemotherapy.
- (and 2 more...)
|
50 |
All |
18 Months to 25 Years (Child, Adult) |
NCT00179803 |
BMT 0398 |
|
March 1998 |
January 2008 |
|
September 16, 2005 |
March 14, 2011 |
|
- Children's Memorial Hospital
Chicago, Illinois, United States
|
| 9 |
NCT00867178 |
Active, not recruiting |
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System |
- Medulloblastoma
- Pineoblastoma
- Supratentorial Embryonal Tumor, Not Otherwise Specified
- (and 3 more...)
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Carboplatin
- Drug: Cisplatin
- (and 8 more...)
|
Interventional |
Not Applicable |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity of proposed vorinostat as graded by the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0
- Feasibility in terms of completing 3 courses of induction therapy
- Prognostic value of histopathological classification of pediatric medulloblastoma by single-nucleotide polymorphism (SNP) analysis and gene expression analysis
- (and 4 more...)
|
62 |
All |
2 Months to 47 Months (Child) |
NCT00867178 |
NCI-2012-03167
PBTC-026
U01CA081457
UM1CA081457 |
|
February 25, 2009 |
December 30, 2017 |
|
March 23, 2009 |
December 12, 2017 |
|
- Children's Hospital Los Angeles
Los Angeles, California, United States - Lucile Packard Children's Hospital Stanford University
Palo Alto, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - (and 12 more...)
|
| 10 |
NCT02194452 |
Withdrawn |
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors |
- Acoustic Schwannoma
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- (and 92 more...)
|
- Radiation: gallium Ga 68-edotreotide
- Procedure: positron emission tomography
- Procedure: computed tomography
- Other: laboratory biomarker analysis
|
Interventional |
Not Applicable |
- Sue O'Dorisio
- National Cancer Institute (NCI)
- Ride for Kids
- University of Iowa
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Change in standardized uptake value (SUV) uptake after gallium Ga 68-edotreotide
- Proportion of discordance and concordance between gallium Ga 68-edotreotide and biopsy
|
0 |
All |
6 Months to 29 Years (Child, Adult) |
NCT02194452 |
201302711
P30CA086862 |
|
September 2013 |
March 2017 |
March 2017 |
July 18, 2014 |
April 28, 2017 |
|
- University of Iowa Hospitals and Clinics
Iowa City, Iowa, United States
|
| 11 |
NCT00983398 |
Recruiting |
Melphalan, Carboplatin, Mannitol, and Sodium Thiosulfate in Treating Patients With Recurrent or Progressive CNS Embryonal or Germ Cell Tumors |
- Adult Central Nervous System Germ Cell Tumor
- Adult Embryonal Tumor With Multilayered Rosettes, C19MC-Altered
- Adult Medulloblastoma
- (and 14 more...)
|
- Drug: Carboplatin
- Drug: Mannitol
- Drug: Melphalan
- (and 3 more...)
|
Interventional |
Phase 1
Phase 2 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
- National Institute of Neurological Disorders and Stroke (NINDS)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose based on the incidence of dose-limiting toxicity, graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 (Phase I)
- Response rate (Phase II)
- Change in neurocognitive assessment scores (Phase II)
- (and 3 more...)
|
55 |
All |
1 Year to 45 Years (Child, Adult) |
NCT00983398 |
IRB00005056
NCI-2013-00790
OHSU-5056
MR00042551
5056
P30CA069533
R01NS044687 |
|
September 17, 2009 |
December 31, 2019 |
December 31, 2020 |
September 24, 2009 |
November 6, 2017 |
|
- University of Minnesota/Masonic Cancer Center
Minneapolis, Minnesota, United States - OHSU Knight Cancer Institute
Portland, Oregon, United States
|
| 12 |
NCT03382158 |
Recruiting |
International PPB Registry for PPB, DICER1 and Associated Conditions |
- Pleuropulmonary Blastoma
- Sertoli-Leydig Cell Tumor
- DICER1 Syndrome
- (and 10 more...)
|
|
Observational |
|
- Children's Hospitals and Clinics of Minnesota
- Children's Research Institute
- Washington University School of Medicine
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Event-free survival
- Overall response to chemotherapy
- Overall survival
- (and 4 more...)
|
100 |
All |
Child, Adult, Senior |
NCT03382158 |
FDAAA |
|
December 6, 2016 |
December 6, 2023 |
December 6, 2026 |
December 22, 2017 |
December 22, 2017 |
|
- Children;s Minnesota
Minneapolis, Minnesota, United States
|
| 13 |
NCT03434262 |
Recruiting |
SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors |
- Anaplastic Astrocytoma
- Anaplastic Ependymoma
- Anaplastic Ganglioglioma
- (and 53 more...)
|
- Drug: Gemcitabine
- Drug: ribociclib
- Drug: sonidegib
- (and 3 more...)
|
Interventional |
Phase 1 |
- St. Jude Children's Research Hospital
- Novartis Pharmaceuticals
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Estimate the Maximum tolerated dose (MTD)/Recommended Phase 2 Dose (RP2D) of each doublet by stratum
- Pharmacokinetics of combination treatment: Stratum A
- Pharmacokinetics of combination treatment: Stratum B
- (and 3 more...)
|
108 |
All |
1 Year to 39 Years (Child, Adult) |
NCT03434262 |
SJDAWN
NCI-2018-00284 |
|
March 5, 2018 |
February 2025 |
March 2025 |
February 15, 2018 |
April 10, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 14 |
NCT00565903 |
Recruiting |
Elucidating the Genetic Basis of the Pleuropulmonary Blastoma (PPB) Familial Cancer Syndrome |
- Pleuropulmonary Blastoma
- Cystic Nephroma
- Sertoli-Leydig Cell Tumor of Ovary
- (and 7 more...)
|
|
Observational |
|
- D. Ashley Hill, M.D.
- Children's Research Institute
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Identify the genetic factors which contribute to the development or progression of pleuropulmonary blastoma
- Define the clinical features of the pleuropulmonary blastoma (PPB) familial cancer syndrome.
|
2000 |
All |
up to 95 Years (Child, Adult, Senior) |
NCT00565903 |
05-0192 / 201012830 |
PPB |
March 2005 |
December 2018 |
December 2020 |
November 30, 2007 |
July 19, 2017 |
|
- Children's National Medical Center
Washington, D.C., District of Columbia, United States
|
| 15 |
NCT01987596 |
Active, not recruiting |
Study of Fixed vs. Flexible Filgrastim to Accelerate Bone Marrow Recovery After Chemotherapy in Children With Cancer |
- Childhood Choroid Plexus Tumor
- Childhood Medulloblastoma
- Childhood Pineoblastoma
- (and 8 more...)
|
|
Interventional |
Phase 3 |
- Barbara Ann Karmanos Cancer Institute
- National Cancer Institute (NCI)
- Children's Hospital of Michigan
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Days to ANC greater than or equal to 1,000/uL from the start of chemotherapy
- Incidence of febrile neutropenia
- Incidence of hospitalization
- (and 6 more...)
|
23 |
All |
1 Year to 25 Years (Child, Adult) |
NCT01987596 |
2013-062
NCI-2013-02001
P30CA022453 |
|
August 2013 |
September 30, 2017 |
September 30, 2017 |
November 19, 2013 |
March 30, 2017 |
|
- Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States
|
| 16 |
NCT02967380 |
Terminated |
Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases |
- Adult Anaplastic (Malignant) Meningioma
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- (and 22 more...)
|
- Procedure: Dynamic Contrast-Enhanced Magnetic Resonance Imaging
- Drug: Gadobenate Dimeglumine
- Drug: Gadobutrol
- Radiation: Gadopentetate Dimeglumine
|
Interventional |
Not Applicable |
- University of Southern California
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Agreement of using Magnevist® or Multihance versus Gadavist® on glioma grading
|
14 |
All |
18 Years and older (Adult, Senior) |
NCT02967380 |
0S-11-6
NCI-2014-01852
D1 2010-10
HS-11-00363
P30CA014089 |
|
December 14, 2011 |
October 14, 2014 |
October 14, 2015 |
November 18, 2016 |
March 27, 2017 |
|
- USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
|
| 17 |
NCT01977677 |
Active, not recruiting |
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma |
- Adult Ependymoblastoma
- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- (and 6 more...)
|
- Radiation: radiation therapy
- Drug: temozolomide
- Drug: plerixafor
- (and 2 more...)
|
Interventional |
Phase 1
Phase 2 |
- Stanford University
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity, defined as the absence of cardiac arrhythmia measured by electrocardiogram (ECG) or grade III or IV adverse events, using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
- Progression free survival based on the Response Assessment for Neuro-Oncology (RANO) criteria, using both clinical examinations and MRIs with and without contrast
|
30 |
All |
18 Years to 75 Years (Adult, Senior) |
NCT01977677 |
BRN0023
NCI-2013-02012
P30CA124435 |
|
November 2014 |
July 2017 |
November 2022 |
November 7, 2013 |
July 28, 2017 |
|
- Stanford University, School of Medicine
Stanford, California, United States
|
| 18 |
NCT01234805 |
Terminated |
Yoga Therapy in Treating Patients With Malignant Brain Tumors |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Meningioma
- (and 20 more...)
|
- Procedure: yoga therapy
- Other: questionnaire administration
- Procedure: quality-of-life assessment
|
Interventional |
Not Applicable |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Estimate the participation rate, accrual, adherence, and retention to a yoga trial in patients with malignant brain tumors
- Self-reported fatigue
- Depressive symptoms
- (and 4 more...)
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT01234805 |
CCCWFU 98410
NCI-2010-02044 |
|
December 2010 |
September 2012 |
|
November 4, 2010 |
August 1, 2017 |
|
- Comprehensive Cancer Center of Wake Forest University
Winston-Salem, North Carolina, United States
|
| 19 |
NCT01119599 |
Completed |
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma |
- Acoustic Schwannoma
- Adult Anaplastic (Malignant) Meningioma
- Adult Anaplastic Astrocytoma
- (and 26 more...)
|
- Radiation: 3-Dimensional Conformal Radiation Therapy
- Drug: Gamma-Secretase Inhibitor RO4929097
- Radiation: Intensity-Modulated Radiation Therapy
- (and 4 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose defined as the highest dose studied for which the incidence of dose limiting toxicity is less than 33% using National Cancer Institute Common Toxicity Criteria
- Changes in MRI parameters
- Percent changes in serum YKL-40 levels and hair follicle HES1 levels
- Pharmacokinetic (PK) parameters of gamma-secretase/Notch signalling pathway inhibitor RO4929097
|
22 |
All |
19 Years and older (Adult, Senior) |
NCT01119599 |
NCI-2011-01410
CDR0000672641
09-177
8556
P30CA008748
U01CA069856 |
|
May 2010 |
June 2013 |
|
May 7, 2010 |
September 29, 2015 |
|
- Memorial Sloan-Kettering Cancer Center
New York, New York, United States - University of Virginia Cancer Center
Charlottesville, Virginia, United States
|
| 20 |
NCT00110032 |
Terminated |
Positron Emission Tomography Using Fluorine F 18 EF5 to Find Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Newly Diagnosed Brain Tumors |
- Adult Anaplastic Astrocytoma
- Adult Anaplastic Ependymoma
- Adult Anaplastic Oligodendroglioma
- (and 24 more...)
|
- Drug: EF5
- Procedure: conventional surgery
- Procedure: positron emission tomography
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Safety of F-18-EF5 based on the NCI CTCAE version 3.0
- Pharmacokinetics of radioactively labeled [F-18]-EF5
- Extent of hypoxia, determined by [F-18]-EF5 PET imaging
- (and 2 more...)
|
46 |
All |
18 Years and older (Adult, Senior) |
NCT00110032 |
NCI-2012-02651
UPCC 01304
CDR0000423313 |
|
June 2005 |
January 2007 |
|
May 4, 2005 |
January 16, 2013 |
|
- Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania, United States
|
| 21 |
NCT02255461 |
Recruiting |
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors |
- Childhood Choroid Plexus Tumor
- Childhood Ependymoblastoma
- Childhood Grade III Meningioma
- (and 16 more...)
|
- Drug: palbociclib isethionate
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- Pediatric Brain Tumor Consortium
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of palbociclib isethionate defined as the highest dose level at which six patients have been treated with at most one patient experiencing a dose limiting toxicity and the next higher dose level has been determined to be too toxic
- Incidence of adverse events
- Objective responses (partial response + complete response)
- (and 2 more...)
|
55 |
All |
4 Years to 21 Years (Child, Adult) |
NCT02255461 |
PBTC-042
U01CA081457 |
|
October 2014 |
December 31, 2018 |
December 31, 2018 |
October 2, 2014 |
September 28, 2017 |
|
- Childrens Hospital Los Angeles
Los Angeles, California, United States - Lucile Packard Children Hospital Stanford University
Palo Alto, California, United States - Childrens National Medical Center
Washington, D.C., District of Columbia, United States - (and 8 more...)
|
| 22 |
NCT01088763 |
Terminated |
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia |
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germinoma
- (and 43 more...)
|
- Drug: gamma-secretase/Notch signalling pathway inhibitor RO4929097
- Other: diagnostic laboratory biomarker analysis
- Other: pharmacological study
- Drug: dexamethasone
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD) of RO4929097 determined according to dose-limiting toxicities (DLTs) graded using Common Terminology Criteria for Adverse Events version 4.0 (CTCAE v4.0)
- MTD of RO4929097 administered with dexamethasone determined according to DLTs graded using CTCAE v4.0
- Antitumor activity of RO4929097 with or without dexamethasone assessed by Response Evaluation Criteria for Solid Tumors (RECIST)
|
129 |
All |
1 Year to 21 Years (Child, Adult) |
NCT01088763 |
NCI-2011-02024
COG-ADVL0919
CDR0000667505
ADVL0919
U01CA097452 |
|
March 2010 |
May 2011 |
May 2011 |
March 17, 2010 |
November 5, 2014 |
|
- Lucile Packard Children's Hospital Stanford University
Palo Alto, California, United States - Stanford University Hospitals and Clinics
Stanford, California, United States - Lurie Children's Hospital-Chicago
Chicago, Illinois, United States - (and 9 more...)
|
| 23 |
NCT01076530 |
Completed |
Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors |
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Embryonal Tumor
- (and 31 more...)
|
- Drug: vorinostat
- Drug: temozolomide
- Other: diagnostic laboratory biomarker analysis
- Other: pharmacological study
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT using NCI CTCAE version 4.0
- Pharmacokinetic parameters of vorinostat in combination with temozolomide
- Response assessed according to RECIST criteria
|
27 |
All |
1 Year to 21 Years (Child, Adult) |
NCT01076530 |
NCI-2011-02011
ADVL0819
CDR0000664388
COG-ADVL0819
U01CA097452 |
|
February 2010 |
October 2012 |
|
February 26, 2010 |
May 3, 2013 |
|
- Childrens Memorial Hospital
Chicago, Illinois, United States - C S Mott Children's Hospital
Ann Arbor, Michigan, United States - University of Minnesota Medical Center-Fairview
Minneapolis, Minnesota, United States - (and 6 more...)
|
| 24 |
NCT00994500 |
Completed |
Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma |
- Childhood Burkitt Lymphoma
- Childhood Central Nervous System Choriocarcinoma
- Childhood Central Nervous System Germ Cell Tumor
- (and 32 more...)
|
- Drug: vorinostat
- Drug: bortezomib
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum-tolerated dose defined as the maximum dose at which fewer than one-third of patients experience DLT according to NCI CTCAE version 3.0
- Disease response assessed according to RECIST criteria
|
20 |
All |
1 Year to 21 Years (Child, Adult) |
NCT00994500 |
NCI-2011-01980
ADVL0916
CDR0000656719
COG-ADVL0916
U01CA097452 |
|
August 2009 |
July 2011 |
|
October 14, 2009 |
July 2, 2013 |
|
- Childrens Memorial Hospital
Chicago, Illinois, United States - Dana-Farber Cancer Institute
Boston, Massachusetts, United States - Columbia University Medical Center
New York, New York, United States - (and 3 more...)
|
| 25 |
NCT00946335 |
Completed |
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors |
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Choroid Plexus Tumor
- (and 25 more...)
|
- Drug: veliparib
- Drug: temozolomide
- Other: pharmacological study
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD or recommended phase II dose of veliparib
- Acute toxicities
- Chronic toxicities
- Plasma drug concentrations and pharmacokinetic parameters, including volume of the central compartment (Vc/F), elimination rate constant (Ke), half-life (t1/2), apparent oral clearance (CL/F), and area under the plasma concentration time curve (AUC)
|
31 |
All |
up to 21 Years (Child, Adult) |
NCT00946335 |
NCI-2012-03177
CDR649727
PBTC-027
U01CA081457 |
|
July 2009 |
October 2011 |
June 2014 |
July 27, 2009 |
July 9, 2014 |
|
- Pediatric Brain Tumor Consortium
Memphis, Tennessee, United States
|
| 26 |
NCT00638898 |
Active, not recruiting |
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor |
- Solid Tumor
- Adult Central Nervous System Germ Cell Tumor
- Adult Rhabdomyosarcoma
- (and 27 more...)
|
- Drug: busulfan
- Drug: melphalan
- Drug: topotecan hydrochloride
- (and 5 more...)
|
Interventional |
Phase 1 |
- City of Hope Medical Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Treatment feasibility in terms of investigational agent-related adverse events of a novel treatment combination followed by peripheral blood stem cell rescue
- Overall survival
- Disease-free survival
- (and 2 more...)
|
25 |
All |
6 Months to 40 Years (Child, Adult) |
NCT00638898 |
03112
NCI-2009-01600 |
|
December 11, 2006 |
April 2019 |
April 2019 |
March 19, 2008 |
March 8, 2018 |
|
- City of Hope
Duarte, California, United States
|
| 27 |
NCT00326664 |
Completed |
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors |
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Cerebral Anaplastic Astrocytoma
- (and 18 more...)
|
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose, defined as the dose at which the model estimates that 25% of patients will experience dose-limiting toxicity as measured by NCI CTCAE v4.0
|
55 |
All |
up to 21 Years (Child, Adult) |
NCT00326664 |
NCI-2009-00709
CDR0000476579
PBTC-020
U01CA081457 |
|
March 2006 |
July 2015 |
July 2015 |
May 17, 2006 |
March 7, 2016 |
|
- UCSF Medical Center-Mount Zion
San Francisco, California, United States - Children's National Medical Center
Washington, District of Columbia, United States - Lurie Children's Hospital-Chicago
Chicago, Illinois, United States - (and 8 more...)
|
| 28 |
NCT00100880 |
Completed |
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors |
- Childhood Atypical Teratoid/Rhabdoid Tumor
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Choroid Plexus Tumor
- (and 23 more...)
|
- Drug: lenalidomide
- Procedure: perfusion-weighted magnetic resonance imaging
- Procedure: diffusion-weighted magnetic resonance imaging
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD, estimated using the modified Continual Reassessment Method (CRM)
- Plasma drug concentrations and pharmacokinetic parameters, including volume of the central compartment (Vc/F), elimination rate constant (Ke), half-life (t1/2), apparent oral clearance (CL/F), and area under the plasma concentration time curve (AUC)
|
45 |
All |
up to 21 Years (Child, Adult) |
NCT00100880 |
NCI-2012-03176
CDR653734
PBTC-018
U01CA081457 |
|
November 2004 |
November 2010 |
|
January 7, 2005 |
September 30, 2013 |
|
- Pediatric Brain Tumor Consortium
Memphis, Tennessee, United States
|
| 29 |
NCT00063973 |
Completed |
Cilengitide in Treating Children With Refractory Primary Brain Tumors |
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Choroid Plexus Tumor
- Childhood Craniopharyngioma
- (and 23 more...)
|
- Drug: cilengitide
- Other: laboratory biomarker analysis
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of cilengitide
- Response
|
24 |
All |
up to 21 Years (Child, Adult) |
NCT00063973 |
NCI-2012-03175
CDR653715
PBTC-012
U01CA081457 |
|
July 2003 |
March 2008 |
|
July 9, 2003 |
September 30, 2013 |
|
- Pediatric Brain Tumor Consortium
Memphis, Tennessee, United States
|
| 30 |
NCT00052780 |
Completed |
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors |
- Childhood Central Nervous System Germ Cell Tumor
- Childhood Choroid Plexus Tumor
- Childhood Craniopharyngioma
- (and 22 more...)
|
- Drug: O6-benzylguanine
- Drug: temozolomide
- Biological: filgrastim
- (and 2 more...)
|
Interventional |
Phase 1 |
- National Cancer Institute (NCI)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- MTD of temozolomide
- Pharmacokinetic parameters
- Acute toxicities
- (and 4 more...)
|
72 |
All |
up to 21 Years (Child, Adult) |
NCT00052780 |
NCI-2012-03174
CDR653709
PBTC-005
U01CA081457 |
|
October 2002 |
November 2007 |
|
January 27, 2003 |
September 30, 2013 |
|
- Pediatric Brain Tumor Consortium
Memphis, Tennessee, United States
|
| 31 |
NCT00085202 |
Active, not recruiting
Has Results |
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor |
- Brain and Central Nervous System Tumors
|
- Biological: filgrastim
- Drug: cisplatin
- Drug: cyclophosphamide
- (and 3 more...)
|
Interventional |
Phase 3 |
- St. Jude Children's Research Hospital
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-Free Survival (PFS) in ERBB2-Negative Tumors Compared to ERBB2-Positive Tumors
- Progression-Free Survival (PFS) Compared Between ERBB2 Assessment and Risk Group.
- Frequency of Mutations Associated With SHH and WNT Tumors
- (and 3 more...)
|
416 |
All |
3 Years to 21 Years (Child, Adult) |
NCT00085202 |
SJMB03
NCI-2011-01185 |
|
August 2003 |
December 2016 |
January 2023 |
June 11, 2004 |
January 23, 2018 |
February 27, 2014 |
- Duke Comprehensive Cancer Center
Durham, North Carolina, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States - St. Jude Children's Research Hospital
Memphis, Tennessee, United States - (and 6 more...)
|
| 32 |
NCT00002647 |
Unknown † |
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors |
- Brain and Central Nervous System Tumors
- Metastatic Cancer
|
- Drug: verteporfin
- Procedure: conventional surgery
|
Interventional |
Phase 1 |
- Medical College of Wisconsin
- National Cancer Institute (NCI)
|
Other |
- Primary Purpose: Treatment
|
|
24 |
All |
3 Years to 70 Years (Child, Adult, Senior) |
NCT00002647 |
CDR0000064165
MCW-7594
MCW-CHW-511
MCW-CHW-9411
NCI-V95-0652 |
|
May 1994 |
|
|
January 27, 2003 |
September 20, 2013 |
|
- Medical College of Wisconsin Cancer Center
Milwaukee, Wisconsin, United States - Midwest Children's Cancer Center at Children's Hospital of Wisconsin
Milwaukee, Wisconsin, United States
|
| 33 |
NCT00445965 |
Active, not recruiting |
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer |
- Brain and Central Nervous System Tumors
- Intraocular Melanoma
- Lung Cancer
- (and 7 more...)
|
- Genetic: DNA analysis
- Other: immunologic technique
- Other: pharmacological study
- (and 2 more...)
|
Interventional |
Phase 2 |
- Memorial Sloan Kettering Cancer Center
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Six-month overall survival
- response rate
- cumulative toxicities
|
78 |
All |
Child, Adult, Senior |
NCT00445965 |
05-122
MSKCC-05122 |
|
January 2006 |
January 2019 |
January 2019 |
March 9, 2007 |
January 17, 2018 |
|
- Memorial Sloan Kettering Cancer Center
New York, New York, United States
|
| 34 |
NCT01009307 |
Completed |
Study of Blood and Cheek Cell Samples From Patients With Glioma |
- Brain and Central Nervous System Tumors
|
- Genetic: polymorphism analysis
- Other: laboratory biomarker analysis
- Other: medical chart review
|
Observational |
|
- University of California, San Francisco
- National Cancer Institute (NCI)
|
Other / NIH |
|
- Factors related to glioma survival
|
1709 |
All |
18 Years and older (Adult, Senior) |
NCT01009307 |
CDR0000437072
UCSF-H6539-04956-13A |
|
October 2001 |
July 2006 |
|
November 6, 2009 |
May 15, 2015 |
|
- UCSF Helen Diller Family Comprehensive Cancer Center
San Francisco, California, United States
|
| 35 |
NCT00967200 |
Completed |
Study of Tissue Samples From Patients With Glioma or Other Brain Tumors |
- Central Nervous System Lymphoma
|
- Other: laboratory biomarker analysis
- Other: pharmacogenomic studies
|
Observational |
|
- University Hospital, Montpellier
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Pathophysiology of gliomas
- Identification of molecular
|
180 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00967200 |
7745 |
|
November 2003 |
July 2009 |
November 2015 |
August 27, 2009 |
November 24, 2015 |
|
- CHU Montpellier
Montpellier, France - Clinique Gui de Chauliac
Montpellier, France
|
| 36 |
NCT00784914 |
Completed |
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors |
- Brain and Central Nervous System Tumors
- Metastatic Cancer
|
- Drug: temsirolimus
- Other: pharmacological study
- Other: cytokine levels
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Non-Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Feasibility of using a microdialysis catheter to assess the neuropharmacodynamics (nPD) of temsirolimus
- Changes in intracerebral levels of vascular endothelial growth factor (VEGF), interleukin-1ß (IL-1ß), and other cytokines
- Relationship between temsirolimus dose and changes in intracerebral levels of VEGF, IL-1ß, and other cytokines
- (and 3 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT00784914 |
07064
P30CA033572
CHNMC-07064
CDR0000617019 |
|
June 2008 |
November 2010 |
November 2010 |
November 4, 2008 |
April 17, 2018 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States
|
| 37 |
NCT00629889 |
Completed |
Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors |
- Brain and Central Nervous System Tumors
- Seizure
|
- Drug: levetiracetam
- Drug: pregabalin
|
Interventional |
Phase 2 |
- Dr Andrea Rossetti
- Centre Hospitalier Universitaire Vaudois
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Supportive Care
|
- Survival without occurrence of status epilepticus, 2 seizures with consciousness impairment, need to add a second antiepileptic drug (AED) (except transitory benzodiazepine), and need to discontinue study drug for lack of efficacy or adverse events
- Adverse events
- Anxiety
- (and 4 more...)
|
52 |
All |
18 Years and older (Adult, Senior) |
NCT00629889 |
CDR0000586523
CHUV-Neurology-CePO-LEV-PGB
EU-20807 |
|
February 2008 |
May 2012 |
May 2013 |
March 6, 2008 |
May 22, 2013 |
|
- Centre Hospitalier Universitaire Vaudois
Lausanne, Switzerland - USZ
Zürich, Switzerland
|
| 38 |
NCT00544284 |
Completed |
Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment |
- Brain and Central Nervous System Tumors
- Lymphoma
- Metastatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific
|
- Drug: bortezomib
- Drug: temozolomide
- Other: pharmacological study
|
Interventional |
Phase 1 |
- City of Hope Medical Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Dose-limiting toxicity and maximum tolerated dose
- Pharmacokinetics
- Confirmed complete or partial response
- Percentage of patients with 6-month progression-free survival
|
25 |
All |
18 Years and older (Adult, Senior) |
NCT00544284 |
04032
P30CA033572
CHNMC-04032
CDR0000570245 |
|
January 2005 |
January 2012 |
January 2012 |
October 16, 2007 |
February 15, 2013 |
|
- City of Hope Comprehensive Cancer Center
Duarte, California, United States - City of Hope Medical Group
Pasadena, California, United States
|
| 39 |
NCT00538850 |
Completed
Has Results |
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain |
|
- Drug: Fentanyl sublingual spray
- Drug: Placebo
|
Interventional |
Phase 3 |
- INSYS Therapeutics Inc
- National Cancer Institute (NCI)
|
Industry / NIH |
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Summed Pain Intensity Differences (SPID) at 30 Minutes After Dosing (SPID30)
- Summed Pain Intensity Differences (SPID) at 5, 10, 15, 45, and 60 Minutes After Dosing
- Total Pain Relief (TOTPAR) at 5, 10, 15, 30, 45, and 60 Minutes After Dosing
- Global Evaluation of the Study Medication at 30 and 60 Minutes After Dosing
|
130 |
All |
18 Years and older (Adult, Senior) |
NCT00538850 |
INS-05-001
CDR0000581128 |
|
October 2007 |
February 2010 |
October 2010 |
October 3, 2007 |
March 5, 2014 |
March 5, 2014 |
- InSys Therapeutics, Incorporated
Chandler, Arizona, United States
|
| 40 |
NCT00499798 |
Completed |
Changes in Semen or Sperm Caused by Temozolomide in Patients With Newly Diagnosed, Progressive, or Recurrent Primary Malignant Brain Tumors |
- Brain and Central Nervous System Tumors
- Chemotherapeutic Agent Toxicity
- Infertility
|
|
Observational |
|
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- assess any changes in standard semen/sperm analysis parameters
|
16 |
Male |
18 Years to 60 Years (Adult) |
NCT00499798 |
CDR0000553297
CCCWFU-97404
CCCWFU-BG04-308 |
|
August 2004 |
June 2009 |
September 2014 |
July 11, 2007 |
May 30, 2017 |
|
- Wake Forest University Comprehensive Cancer Center
Winston-Salem, North Carolina, United States
|
| 41 |
NCT00369785 |
Completed
Has Results |
Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors |
- Brain Tumors
- Metastatic Disease
|
- Drug: donepezil hydrochloride
- Drug: Placebo
|
Interventional |
Phase 3 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
|
- Memory as Quantified by HVLT-immediate Recall
- Memory as Quantified by the HVLT-discrimination
|
198 |
All |
18 Years and older (Adult, Senior) |
NCT00369785 |
REBACCCWFU 91105
U10CA081851 |
|
January 2008 |
December 2011 |
June 2012 |
August 29, 2006 |
December 21, 2017 |
March 9, 2017 |
- Associates in Womens Health, PA - North Review
Wichita, Kansas, United States - Cancer Center of Kansas, PA - Medical Arts Tower
Wichita, Kansas, United States - Cancer Center of Kansas, PA - Wichita
Wichita, Kansas, United States - (and 13 more...)
|
| 42 |
NCT00255671 |
Completed |
Acute Side Effects in Patients Who Are Undergoing Stereotactic Radiosurgery for Brain Tumors or Other Brain Disorders |
- Brain and Central Nervous System Tumors
- Metastatic Cancer
- Radiation Toxicity
|
|
Observational |
|
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Short-term adverse effects as assessed by a questionnaire
|
76 |
All |
18 Years and older (Adult, Senior) |
NCT00255671 |
CASE4Z05
P30CA043703
CCF-8078 |
|
May 2005 |
April 2008 |
May 2012 |
November 21, 2005 |
October 2, 2015 |
|
- Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, United States
|
| 43 |
NCT00253721 |
Terminated |
Melphalan With BBBD in Treating Patients With Brain Malignancies |
- Brain and Central Nervous System Tumors
- Lymphoma
- Metastatic Cancer
|
|
Interventional |
Phase 1 |
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Maximum tolerated dose (MTD)of Melphalan as measured by NCI common toxicity criteria (CTC) v2 toxicities
- Efficacy of chemotherapy regimen as measured by clinical and radiographic response from first day of treatment
|
21 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00253721 |
IRB00001299
P30CA069533
1299
ONC-98018-L
4834 |
|
May 1998 |
December 2015 |
December 2016 |
November 15, 2005 |
April 21, 2017 |
|
- Knight Cancer Institute at Oregon Health and Science University
Portland, Oregon, United States
|
| 44 |
NCT00005790 |
Withdrawn |
Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors |
- Brain and Central Nervous System Tumors
|
- Other: laboratory biomarker analysis
- Procedure: biopsy
- Procedure: magnetic resonance imaging
- Radiation: gadopentetate dimeglumine
|
Interventional |
Not Applicable |
- Northwestern University
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Diagnostic
|
|
0 |
All |
18 Years and older (Adult, Senior) |
NCT00005790 |
NU 95C1
NU-95C1
NCI-G00-1738 |
|
April 1996 |
May 1999 |
May 1999 |
June 9, 2004 |
June 11, 2012 |
|
|
| 45 |
NCT00006368 |
Completed |
Yttrium Y 90 SMT 487 in Treating Patients With Refractory or Recurrent Cancer |
- Brain and Central Nervous System Tumors
- Breast Cancer
- Gastrointestinal Carcinoid Tumor
- (and 5 more...)
|
- Radiation: yttrium Y 90-edotreotide
|
Interventional |
Phase 1 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Primary Purpose: Treatment
|
|
60 |
All |
18 Years and older (Adult, Senior) |
NCT00006368 |
NOVARTIS-SMT-B151
MCC-12275
MCC-IRB-5473
CDR0000068241
NCI-G00-1857 |
|
January 1998 |
November 2003 |
November 2003 |
April 2, 2004 |
May 1, 2013 |
|
- H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States
|
| 46 |
NCT00070161 |
Completed |
Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor |
- Brain and Central Nervous System Tumors
- Radiation Toxicity
|
- Dietary Supplement: EGb761
- Drug: donepezil hydrochloride
- Procedure: cognitive assessment
|
Interventional |
Phase 2 |
- Wake Forest University Health Sciences
- National Cancer Institute (NCI)
|
Other / NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double
- Primary Purpose: Supportive Care
|
|
68 |
All |
18 Years to 120 Years (Adult, Senior) |
NCT00070161 |
REBACCCWFU-97100
U10CA081851 |
|
July 2001 |
May 2005 |
August 2012 |
October 7, 2003 |
November 29, 2017 |
|
- CCOP - Western Regional, Arizona
Phoenix, Arizona, United States - Regional Radiation Oncology Center at Rome
Rome, Georgia, United States - Comprehensive Cancer Center at Wake Forest University
Winston-Salem, North Carolina, United States - CCOP - Upstate Carolina
Spartanburg, South Carolina, United States
|
| 47 |
NCT00008086 |
Completed |
Calcitriol Plus Carboplatin in Treating Patients With Advanced Solid Tumors |
- Brain and Central Nervous System Tumors
- Unspecified Adult Solid Tumor, Protocol Specific
|
- Dietary Supplement: calcitriol
- Drug: carboplatin
|
Interventional |
Phase 1 |
- University of Pittsburgh
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
18 Years and older (Adult, Senior) |
NCT00008086 |
97-004
CDR0000068374
PCI-IRB-970532
NCI-G00-1885 |
|
January 1996 |
September 2004 |
September 2004 |
September 4, 2003 |
December 19, 2013 |
|
- University of Pittsburgh Cancer Institute
Pittsburgh, Pennsylvania, United States
|
| 48 |
NCT00049296 |
Completed |
Thalidomide and Docetaxel in Treating Patients With Advanced Cancer |
|
- Drug: docetaxel
- Drug: thalidomide
|
Interventional |
Phase 1 |
- Case Comprehensive Cancer Center
- National Cancer Institute (NCI)
|
Other / NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Determine the maximum tolerated dose of docetaxel when administered with thalidomide in patients with advanced solid tumors, multiple myeloma, and non-Hodgkin's lymphoma.
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT00049296 |
CWRU4Y01
P30CA043703
CWRU-4Y01
NCI-G02-2123 |
|
July 2002 |
December 2004 |
January 2006 |
January 27, 2003 |
June 11, 2010 |
|
- Ireland Cancer Center at University Hospitals Case Medical Center, Case Comprehensive Cancer Center
Cleveland, Ohio, United States
|
| 49 |
NCT00025558 |
Completed |
Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Brain Cancer |
- Brain and Central Nervous System Tumors
|
- Biological: filgrastim
- Drug: carboplatin
- Drug: temozolomide
- (and 3 more...)
|
Interventional |
Phase 1 |
- New York University School of Medicine
- National Cancer Institute (NCI)
|
Other / NIH |
- Primary Purpose: Treatment
|
|
|
All |
1 Year to 49 Years (Child, Adult) |
NCT00025558 |
CDR0000068973
P30CA016087
NYU-0006H
NCI-G01-2022 |
|
October 2000 |
May 2007 |
|
January 27, 2003 |
March 28, 2011 |
|
- NYU Cancer Institute at New York University Medical Center
New York, New York, United States - Columbus Children's Hospital
Columbus, Ohio, United States - Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, United States - Princess Margaret Hospital for Children
Perth, Western Australia, Australia
|
| 50 |
NCT00019019 |
Completed |
Carboxyamidotriazole and Paclitaxel in Treating Patients With Advanced Solid Tumors or Refractory Lymphomas |
- Brain and Central Nervous System Tumors
- Breast Cancer
- Kidney Cancer
- (and 6 more...)
|
- Drug: carboxyamidotriazole
- Drug: paclitaxel
|
Interventional |
Phase 1 |
- National Institutes of Health Clinical Center (CC)
- National Cancer Institute (NCI)
|
NIH |
- Primary Purpose: Treatment
|
|
70 |
All |
18 Years and older (Adult, Senior) |
NCT00019019 |
950015
95-C-0015
NCI-CPB-334
NCI-T94-0006N
CDR0000063881 |
|
October 1994 |
July 2006 |
July 2006 |
January 27, 2003 |
March 15, 2012 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States - NCI - Medical Oncology Clinical Research Unit
Bethesda, Maryland, United States
|
Create an RSS feed from your search for:
Download the search results for: